Tegaserod for the Treatment of Irritable Bowel Syndrome

Author(s): Valentina Noemi Madia, Antonella Messore, Francesco Saccoliti, Valeria Tudino, Alessandro De Leo, Daniela De Vita, Martina Bortolami, Luigi Scipione, Ivano Pindinello, Roberta Costi*, Roberto Di Santo

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 19 , Issue 4 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract associated with the irritable bowel syndrome with constipation (IBS-C).

Objective: The authors provide the reader with a better understanding on tegaserod mechanism of action, on its pharmacodynamics and pharmacokinetic properties, on safety and tolerability, with a summary of the key published clinical trials conducted in patients with irritable bowel syndrome (IBS). Its effects on colon inflammation have also been described.

Results: Tegaserod was withdrawn in 2007 due to increased risks of cardiovascular adverse effects. The manufacturer denied this, because pre-existing cardiovascular disease or risk factors were attributed to all affected patients. Thus, no causal relationship between tegaserod use and cardiovascular events was clearly shown. A matched case-control study of tegaserod-treated with untreated patients found no association between tegaserod and adverse cardiovascular outcomes. Despite its adverse effects, tegaserod resulted to be effective in treating chronic constipation in adult women aged < 65 years with IBS-C, while the safety and effectiveness of tegaserod in men with IBS-C have not been established.

Conclusion: Tegaserod was resubmitted to the Food and Drug Administration in 2018 for use in a low-risk population. Moreover, tegaserod has also been shown to improve symptoms, enhance gastric accommodation and significantly attenuate visceral pain arising from the colon in functional dyspepsia patients. Treatment with tegaserod seems also to exert a protective effect in inflamed colons, reducing the severity of colitis in animal models.

Keywords: 5-HT4 agonist, abdominal pain, chronic bowel disorder, clinical trials, constipation, irritable bowel syndrome, tegaserod maleate, Zelnorm®.

[1]
Lovell, R.M.; Ford, A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta analysis. Clin. Gastroenterol. Hepatol., 2012, 10(7), 712-721.e4.
[http://dx.doi.org/10.1016/j.cgh.2012.02.029] [PMID: 22426087]
[2]
Moayyedi, P.; Andrews, C.N.; MacQueen, G.; Korownyk, C.; Marsiglio, M.; Graff, L.; Kvern, B.; Lazarescu, A.; Liu, L.; Paterson, W.G.; Sidani, S.; Vanner, S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol., 2019, 2(1), 6-29.
[http://dx.doi.org/10.1093/jcag/gwy071] [PMID: 31294724]
[3]
Moayyedi, P.; Marsiglio, M.; Andrews, C.N.; Graff, L.A.; Korownyk, C.; Kvern, B.; Lazarescu, A.; Liu, L.; MacQueen, G.; Paterson, W.G.; Sidani, S.; Vanner, S.J.; Sinclair, P.; Marshall, L.; Fernandes, A. Patient engagement and multidisciplinary involvement has an impact on clinical guideline development and decisions: a comparison of two irritable bowel syndrome guidelines using the same data. J. Can. Assoc. Gastroenterol., 2019, 2(1), 30-36.
[http://dx.doi.org/10.1093/jcag/gwy072] [PMID: 31294725]
[4]
Faresjö, Å.; Walter, S.; Norlin, A.K.; Faresjö, T.; Jones, M.P. Gastrointestinal symptoms - an illness burden that affects daily work in patients with IBS. Health Qual. Life Outcomes, 2019, 17(1), 113.
[http://dx.doi.org/10.1186/s12955-019-1174-1] [PMID: 31262316]
[5]
Rubin, G.; De Wit, N.; Meineche-Schmidt, V.; Seifert, B.; Hall, N.; Hungin, P. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam. Pract., 2006, 23(6), 687-692.
[http://dx.doi.org/10.1093/fampra/cml050] [PMID: 17062586]
[6]
Casiday, R.E.; Hungin, A.P.; Cornford, C.S.; de Wit, N.J.; Blell, M.T. GPs’ explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam. Pract., 2009, 26(1), 34-39.
[http://dx.doi.org/10.1093/fampra/cmn088] [PMID: 19011171]
[7]
Bijkerk, C.J.; de Wit, N.J.; Stalman, W.A.; Knottnerus, J.A.; Hoes, A.W.; Muris, J.W. Irritable bowel syndrome in primary care: the patients’ and doctors’ views on symptoms, etiology and management. Can. J. Gastroenterol., 2003, 17(6), 363-368.
[http://dx.doi.org/10.1155/2003/532138] [PMID: 12813601]
[8]
Moussa, L.; Bézirard, V.; Salvador-Cartier, C.; Bacquié, V.; Houdeau, E.; Théodorou, V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin. Nutr., 2013, 32(1), 51-58.
[http://dx.doi.org/10.1016/j.clnu.2012.05.021] [PMID: 22727545]
[9]
Zhang, J.J.; Ma, H.; Zhu, J.Z.; Lu, C.; Yu, C.H.; Li, Y.M. The role of dietary energy and macronutrients intake in prevalence of irritable bowel syndromes. BioMed Res. Int., 2019, 2019, 8967306.
[http://dx.doi.org/10.1155/2019/8967306] [PMID: 31223623]
[10]
Zhang, F.M.; Li, S.; Ding, L.; Xiang, S.H.; Zhu, H.T.; Yu, J.H.; Xu, G.Q. Effectiveness of mesalazine to treat irritable bowel syndrome: a meta-analysis. Medicine (Baltimore), 2019, 98(28), e16297.
[http://dx.doi.org/10.1097/MD.0000000000016297] [PMID: 31305414]
[11]
Lopes, S.S.; Miszputen, S.J.; Sachs, A.; Lima, M.M.; Ambrogini, O., Jr Evaluation of carbohydrate and fiber consumption in patients with irritable bowel syndrome in outpatient treatment. Arq. Gastroenterol., 2019, 56(1), 3-9.
[http://dx.doi.org/10.1590/s0004-2803.201900000-12] [PMID: 31141064]
[12]
Liang, D.; Longgui, N.; Guoqiang, X. Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis. Medicine (Baltimore), 2019, 98(27), e16068.
[http://dx.doi.org/10.1097/MD.0000000000016068] [PMID: 31277101]
[13]
Tack, J.; Stanghellini, V.; Mearin, F.; Yiannakou, Y.; Layer, P.; Coffin, B.; Simren, M.; Mackinnon, J.; Wiseman, G.; Marciniak, A. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol., 2019, 19(1), 69.
[http://dx.doi.org/10.1186/s12876-019-0985-1] [PMID: 31064345]
[14]
Guerreiro, M.; Sousa Guerreiro, C.; Cravo, M. Irritable bowel syndrome: how can symptoms and quality of life be improved with diet? Curr. Opin. Clin. Nutr. Metab. Care, 2019, 22(5), 377-382.
[http://dx.doi.org/10.1097/MCO.0000000000000589]]
[15]
Sanger, G.J.; Alpers, D.H. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol. Motil., 2008, 20(3), 177-184.
[http://dx.doi.org/10.1111/j.1365-2982.2008.01084.x] [PMID: 18257767]
[16]
Baj, A.; Moro, E.; Bistoletti, M.; Orlandi, V.; Crema, F.; Giaroni, C. Glutamatergic signaling along the microbiota-gut-brain axis. Int. J. Mol. Sci., 2019, 20(6), E1482.
[http://dx.doi.org/10.3390/ijms20061482] [PMID: 30934533]
[17]
Baker, D.E. Rationale for using serotonergic agents to treat irritable bowel syndrome. Am. J. Health Syst. Pharm., 2005, 62(7), 700-711.
[http://dx.doi.org/10.1093/ajhp/62.7.700] [PMID: 15790796]
[18]
Di Stefano, M.V.R.; Sifrim, D.; Tack, J. Effects of buspirone, a 5-HT1A receptor agonist, on oesophagea peristalsis and lower esophageal sphincter function in healthy volunteers. Gastroenterology, 2004, 126, A638.
[19]
Borman, R.A.; Tilford, N.S.; Harmer, D.W.; Day, N.; Ellis, E.S.; Sheldrick, R.L.; Carey, J.; Coleman, R.A.; Baxter, G.S. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br. J. Pharmacol., 2002, 135(5), 1144-1151.
[http://dx.doi.org/10.1038/sj.bjp.0704571] [PMID: 11877320]
[20]
Crowell, M.D. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am. J. Manag. Care, 2001, 7(8)(Suppl.), S252-S260.
[PMID: 11474910]
[21]
Briejer, M.R.; Akkermans, L.M.; Schuurkes, J.A. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol. Rev., 1995, 47(4), 631-651.
[PMID: 8746557]
[22]
Langlois, M.; Fischmeister, R. 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem., 2003, 46(3), 319-344.
[http://dx.doi.org/10.1021/jm020099f] [PMID: 12540230]
[23]
Williams, M. The Merck Index: an Encyclopedia of Chemicals; Drugs, and Biologicals, 2013, p. 1628.
[24]
Beattie, D.T.; Smith, J.A.; Marquess, D.; Vickery, R.G.; Armstrong, S.R.; Pulido-Rios, T.; McCullough, J.L.; Sandlund, C.; Richardson, C.; Mai, N.; Humphrey, P.P. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol., 2004, 143(5), 549-560.
[http://dx.doi.org/10.1038/sj.bjp.0705929] [PMID: 15466450]
[25]
Evans, B.W.; Clark, W.K.; Moore, D.J.; Whorwell, P.J. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst. Rev., 2007, 4(4), CD003960.
[http://dx.doi.org/10.1002/14651858.CD003960.pub3] [PMID: 17943807]
[26]
Rivkin, A. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin. Ther., 2003, 25(7), 1952-1974.
[http://dx.doi.org/10.1016/S0149-2918(03)80198-4] [PMID: 12946544]
[27]
Rossi, S. Australian Medicines Handbook, AMH Pty Ltd: Australia; 27th ed, 2004.
[28]
Marciniak, T.A.; Serebruany, V. Should we use tegaserod for irritable bowel syndrome? Am. J. Ther., 2019, 26(3), e417-e420.
[http://dx.doi.org/10.1097/MJT.0000000000000947] [PMID: 30946048]
[29]
Morganroth, J.; Rüegg, P.C.; Dunger-Baldauf, C.; Appel-Dingemanse, S.; Bliesath, H.; Lefkowitz, M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol., 2002, 97(9), 2321-2327.
[http://dx.doi.org/10.1111/j.1572-0241.2002.05986.x] [PMID: 12358251]
[30]
Müller-Lissner, S.; Holtmann, G.; Rueegg, P.; Weidinger, G.; Löffler, H. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther., 2005, 21(1), 11-20.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02294.x] [PMID: 15644040]
[31]
Novick, J.; Miner, P.; Krause, R.; Glebas, K.; Bliesath, H.; Ligozio, G.; Rüegg, P.; Lefkowitz, M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther., 2002, 16(11), 1877-1888.
[http://dx.doi.org/10.1046/j.1365-2036.2002.01372.x] [PMID: 12390096]
[32]
Tack, J.; Müller-Lissner, S.; Bytzer, P.; Corinaldesi, R.; Chang, L.; Viegas, A.; Schnekenbuehl, S.; Dunger-Baldauf, C.; Rueegg, P. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut, 2005, 54(12), 1707-1713.
[http://dx.doi.org/10.1136/gut.2005.070789] [PMID: 16020489]
[33]
Tegaserod, N.D.A. 21-200 Supplements., Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021200Orig1s015lbl.pdf[Accessed May 17, 2019].
[34]
Buchheit, K.H.; Gamse, R.; Giger, R.; Hoyer, D.; Klein, F.; Klöppner, E.; Pfannkuche, H.J.; Mattes, H. The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J. Med. Chem., 1995, 38(13), 2331-2338.
[http://dx.doi.org/10.1021/jm00013a010] [PMID: 7608899]
[35]
De Maeyer, J.H.; Lefebvre, R.A.; Schuurkes, J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil., 2008, 20(2), 99-112.
[http://dx.doi.org/10.1111/j.1365-2982.2007.01059.x] [PMID: 18199093]
[36]
Tonini, M.; Pace, F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig. Dis., 2006, 24(1-2), 59-69.
[http://dx.doi.org/10.1159/000090309] [PMID: 16699264]
[37]
Tonini, M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol. Motil., 2005, 17(5), 637-642.
[http://dx.doi.org/10.1111/j.1365-2982.2005.00716.x] [PMID: 16185301]
[38]
Jin, M.; Mo, Y.; Ye, K.; Chen, M.; Liu, Y.; He, C. Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis. Arch. Med. Sci., 2019, 15(1), 23-32.
[http://dx.doi.org/10.5114/aoms.2017.69234] [PMID: 30697251]
[39]
Pittayanon, R.; Yuan, Y.; Bollegala, N.P.; Khanna, R.; Leontiadis, G.I.; Moayyedi, P. Prokinetics for functional dyspepsia. Cochrane Database Syst. Rev., 2018, 10, CD009431
[PMID: 30335201]
[40]
Spohn, S.N.; Bianco, F.; Scott, R.B.; Keenan, C.M.; Linton, A.A.; O’Neill, C.H.; Bonora, E.; Dicay, M.; Lavoie, B.; Wilcox, R.L.; MacNaughton, W.K.; De Giorgio, R.; Sharkey, K.A.; Mawe, G.M. Protective actions of epithelial 5-hydroxytryptamine 4 receptors in normal and inflamed colon. Gastroenterology, 2016, 151(5), 933-944.e3.
[http://dx.doi.org/10.1053/j.gastro.2016.07.032] [PMID: 27480173]
[41]
Sun, Y.N.; Luo, J.Y. Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord. World J. Gastroenterol., 2004, 10(12), 1830-1833.
[http://dx.doi.org/10.3748/wjg.v10.i12.1830] [PMID: 15188517]
[42]
Crowell, M.D. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol., 2004, 141(8), 1285-1293.
[http://dx.doi.org/10.1038/sj.bjp.0705762] [PMID: 15100164]
[43]
Hegde, S.S.; Eglen, R.M. Peripheral 5-HT4 receptors. FASEB J., 1996, 10(12), 1398-1407.
[http://dx.doi.org/10.1096/fasebj.10.12.8903510] [PMID: 8903510]
[44]
Mawe, G.M.; Hoffman, J.M. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol., 2013, 10(8), 473-486.
[http://dx.doi.org/10.1038/nrgastro.2013.105] [PMID: 23797870]
[45]
Liu, M.T.; Kuan, Y.H.; Wang, J.; Hen, R.; Gershon, M.D. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J. Neurosci., 2009, 29(31), 9683-9699.
[http://dx.doi.org/10.1523/JNEUROSCI.1145-09.2009] [PMID: 19657021]
[46]
Bertrand, P.P. Real-time detection of serotonin release from enterochromaffin cells of the guinea-pig ileum. Neurogastroenterol. Motil., 2004, 16(5), 511-514.
[http://dx.doi.org/10.1111/j.1365-2982.2004.00572.x] [PMID: 15500507]
[47]
Hoffman, J.M.; Tyler, K.; MacEachern, S.J.; Balemba, O.B.; Johnson, A.C.; Brooks, E.M.; Zhao, H.; Swain, G.M.; Moses, P.L.; Galligan, J.J.; Sharkey, K.A.; Greenwood-Van Meerveld, B.; Mawe, G.M. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology, 2012, 142(4), 844-854.e4.
[http://dx.doi.org/10.1053/j.gastro.2011.12.041] [PMID: 22226658]
[48]
Scott, L.J.; Perry, C.M. Tegaserod. Drugs, 1999, 58(3), 491-496.
[http://dx.doi.org/10.2165/00003495-199958030-00013] [PMID: 10493276]
[49]
Saad, R.; Chey, W.D. Tegaserod in the treatment of irritable bowel syndrome with constipation. Womens Health (Lond), 2006, 2(1), 29-42.
[http://dx.doi.org/10.2217/17455057.2.1.29] [PMID: 19803924]
[50]
Jadallah, K.A.; Kullab, S.M.; Sanders, D.S. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J. Gastroenterol., 2014, 20(27), 8898-8909.
[PMID: 25083062]
[51]
Taniyama, K.; Nakayama, S.; Takeda, K.; Matsuyama, S.; Shirakawa, J.; Sano, I.; Tanaka, C. Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J. Pharmacol. Exp. Ther., 1991, 258(3), 1098-1104.
[PMID: 1890614]
[52]
Edwards, C.A.; Holden, S.; Brown, C.; Read, N.W. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut, 1987, 28(1), 13-16.
[http://dx.doi.org/10.1136/gut.28.1.13] [PMID: 3817579]
[53]
Krevsky, B.; Malmud, L.S.; Maurer, A.H.; Somers, M.B.; Siegel, J.A.; Fisher, R.S. The effect of oral cisapride on colonic transit. Aliment. Pharmacol. Ther., 1987, 1(4), 293-304.
[http://dx.doi.org/10.1111/j.1365-2036.1987.tb00629.x] [PMID: 2979674]
[54]
Farup, P.G.; Hovdenak, N.; Wetterhus, S.; Lange, O.J.; Hovde, O.; Trondstad, R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand. J. Gastroenterol., 1998, 33(2), 128-131.
[http://dx.doi.org/10.1080/00365529850166833] [PMID: 9517521]
[55]
Lewis, C. The impact of direct-to-consumer advertising. FDA Consum., 2003, 37(2), 8.
[PMID: 12715762]
[56]
De Knaep, A.G.M.; Moens, L.J.R.; Rey, M. Synthesis of cisapride. International Patent WO/1998/016511, 1998.April 23.
[57]
Palmer, R.M.J.; Meyers, N.L.; Knight, J. Process for the preparation of renzapride and intermediates thereof. European Patent EP1664048 (A2), 2006.June 07.
[58]
Lee, M.J.; Choi, S. Im, W. 5-HT4 Receptor agonists in the treatment of gastrointestinal motility disorders: current status and perspective. Int. J. Gastroenterol. Disorder, 2014, 1, 108-115.
[59]
Noverola, A.V.; Soto, J.P.; Spickett, R.G.W. Aromatic amides of heterocyclic compounds and therapeutic compositions containing same. U.S. Patent 4,138,492, 1979.February 6.
[60]
Vukics, K.; Fischer, J.; Lévai, S.; Erdélyi, P. Process for the synthesis of mosapride. International Patent WO/2003/106440, 2003.December 24.
[61]
Coremans, G.; Kerstens, R.; De Pauw, M.; Stevens, M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo controlled clinical trial. Digestion, 2003, 67(1-2), 82-89.
[http://dx.doi.org/10.1159/000070202] [PMID: 12743445]
[62]
Chai, Y.; Xu, D.; Gong, Y.; Zheng, L.; Qian, W.; Yang, Z.; Tian, Z.; Lv, F.; Yuan, F. Synthesis process of prucalopride. Chinese Patent CN103664912, 2014.March 26.
[63]
Long, D.D.; Armstrong, S.R.; Beattie, D.T.; Choi, S.K.; Fatheree, P.R.; Gendron, R.A.; Genov, D.; Goldblum, A.A.; Humphrey, P.P.; Jiang, L.; Marquess, D.G.; Shaw, J.P.; Smith, J.A.; Turner, S.D.; Vickery, R.G. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of concept in patients with chronic idiopathic constipation. Bioorg. Med. Chem. Lett., 2012, 22(19), 6048-6052.
[http://dx.doi.org/10.1016/j.bmcl.2012.08.051] [PMID: 22959244]
[64]
Henschke, J.P.; Liu, Y.; Xia, L.; Chen, Y.F. Process for the preparation of lubiprostone. U.S. Patent 8,846,958 B2, 2014.September 30.
[65]
Chen, X.; Wu, J.; Mi, P.; Tao, A.; Yuan, J. Linaclotide synthesis method. International Patent WO/2017/101810, 2017.June 22.
[66]
Mi, P.; Pan, J.; Ma, Y.; Yuan, J. Preparation method of plecanatide. Chinese Patent CN104211777, 2014.December 17.
[67]
Starke, I.; Dahlstrom, M.; Blomberg, D. Chemical compounds.International Patent WO/2002/050051, 2002.June 27.
[68]
Americal Gastroenterological Association medical position statement: Irritable bowel syndrome. Gastroenterol., 2002, 123, 2105-2107.
[http://dx.doi.org/10.1053/gast.2002.37095b]
[69]
Frissora, C.L. A new look at irritable bowel syndrome [IBS]: a neuroenteric disorder. Compr. Ther., 2002, 28(3), 222-231.
[http://dx.doi.org/10.1007/s12019-002-0031-y] [PMID: 12360634]
[70]
Poynard, T.; Naveau, S.; Mory, B.; Chaput, J.C. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 1994, 8(5), 499-510.
[http://dx.doi.org/10.1111/j.1365-2036.1994.tb00322.x] [PMID: 7865642]
[71]
Camilleri, M. Management of the irritable bowel syndrome. Gastroenterology, 2001, 120(3), 652-668.
[http://dx.doi.org/10.1053/gast.2001.21908] [PMID: 11179242]
[72]
Quigley, E.M. Cisapride: what can we learn from the rise and fall of a prokinetic? J. Dig. Dis., 2011, 12(3), 147-156.
[http://dx.doi.org/10.1111/j.1751-2980.2011.00491.x] [PMID: 21615867]
[73]
World Health Organization; Pharmaceuticals: restrictions in use and availability., Available from: https://apps.who.int/medicinedocs/pdf/s2203e/s2203e.pdf(Accessed May 17, 2019).
[74]
Meyers, N.L.; Hickling, R.I. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J. Int. Med. Res., 2007, 35(6), 848-866.
[http://dx.doi.org/10.1177/147323000703500613] [PMID: 18034998]
[75]
Scarpellini, E.; Tack, J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin. Investig. Drugs, 2008, 17(11), 1663-1670.
[http://dx.doi.org/10.1517/13543784.17.11.1663] [PMID: 18922103]
[76]
Ford, A.C.; Brandt, L.J.; Young, C.; Chey, W.D.; Foxx-Orenstein, A.E.; Moayyedi, P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol., 2009, 104(7), 1831-1843.
[http://dx.doi.org/10.1038/ajg.2009.223] [PMID: 19471254]
[77]
Schoenfeld, P. Review article: the safety profile of tegaserod. Aliment. Pharmacol. Ther., 2004, 20(Suppl. 7), 25-30.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02182.x] [PMID: 15521852]
[78]
Hasler, W.L.; Schoenfeld, P. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Saf., 2004, 27(9), 619-631.
[http://dx.doi.org/10.2165/00002018-200427090-00001] [PMID: 15230644]
[79]
Shin, A.; Camilleri, M.; Kolar, G.; Erwin, P.; West, C.P.; Murad, M.H. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment. Pharmacol. Ther., 2014, 39(3), 239-253.
[http://dx.doi.org/10.1111/apt.12571] [PMID: 24308797]
[80]
Sun, J.; Yuan, Y.Z.; Holtmann, G. Itopride in the treatment of functional dyspepsia in Chinese patients: a prospective, multicentre, post-marketing observational study. Clin. Drug Investig., 2011, 31(12), 865-875.
[http://dx.doi.org/10.1007/BF03256924] [PMID: 22035464]
[81]
Barish, C.F.; Drossman, D.; Johanson, J.F.; Ueno, R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig. Dis. Sci., 2010, 55(4), 1090-1097.
[http://dx.doi.org/10.1007/s10620-009-1068-x] [PMID: 20012484]
[82]
Rao, S.; Lembo, A.J.; Shiff, S.J.; Lavins, B.J.; Currie, M.G.; Jia, X.D.; Shi, K.; MacDougall, J.E.; Shao, J.Z.; Eng, P.; Fox, S.M.; Schneier, H.A.; Kurtz, C.B.; Johnston, J.M. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am. J. Gastroenterol., 2012, 107(11), 1714-1724.
[http://dx.doi.org/10.1038/ajg.2012.255] [PMID: 22986440]
[83]
Lacy, B.E.; Levenick, J.M.; Crowell, M. Chronic constipation: new diagnostic and treatment approaches. Therap. Adv. Gastroenterol., 2012, 5(4), 233-247.
[http://dx.doi.org/10.1177/1756283X12443093] [PMID: 22778789]
[84]
Rao, A.S.; Wong, B.S.; Camilleri, M.; Odunsi-Shiyanbade, S.T.; McKinzie, S.; Ryks, M.; Burton, D.; Carlson, P.; Lamsam, J.; Singh, R.; Zinsmeister, A.R. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology, 2010, 139(5), 1549-1558.e1.
[http://dx.doi.org/10.1053/j.gastro.2010.07.052] [PMID: 20691689]
[85]
Wong, B.S.; Camilleri, M.; McKinzie, S.; Burton, D.; Graffner, H.; Zinsmeister, A.R. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am. J. Gastroenterol., 2011, 106(12), 2154-2164.
[http://dx.doi.org/10.1038/ajg.2011.285] [PMID: 21876564]
[86]
Low, K.; Hwang, L.; Hua, J.; Zhu, A.; Morales, W.; Pimentel, M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J. Clin. Gastroenterol., 2010, 44(8), 547-550.
[PMID: 19996983]
[87]
Gaitonde, A.; Mnaojkumar, B.; Sonawane, S. Synthesis of tegaserod or a salt thereof. U.S. Patent 2009/306170 A1, 2009.December 10.
[88]
Zimmemann, A.E. Tegaserod: a 5-HT4 agonist for women with constipation-predominant irritable bowel syndrome. Fomulary, 2002, 37, 449-461.
[89]
Pfannkuche, H.J.; Buhl, T.; Gamse, R.; Hoyer, D.; Mattes, H.; Buchheit, K.H. The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol. Motil., 1995, 7, 280.
[90]
Sanger, G.J.; Wardle, K.A.; Shapcott, S.; Yee, F.K. Constipation evoked by 5-HT3 receptor antagonists. Serotonin: molecular biology, receptors and functional effects, Springer Nature Switzerland: Birkhäuser Basel,, 1991, pp. 381-388.
[http://dx.doi.org/10.1007/978-3-0348-7259-1_37]
[91]
Sowers, J.R.; Sharp, B.; McCallum, R.W. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J. Clin. Endocrinol. Metab., 1982, 54(4), 869-871.
[http://dx.doi.org/10.1210/jcem-54-4-869] [PMID: 7037817]
[92]
Burks, T.F.; Long, J.P. Catecholamine‐induced release of 5–hydroxytryptamine (5‐HT) from perfused vasculature of isolated dog intestine. J. Pharm. Sci., 1966, 55(12), 1383-1386.
[http://dx.doi.org/10.1002/jps.2600551211]
[93]
Grider, J.R.; Foxx-Orenstein, A.E.; Jin, J.G. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology, 1998, 115(2), 370-380.
[http://dx.doi.org/10.1016/S0016-5085(98)70203-3] [PMID: 9679042]
[94]
Jin, J.G.; Foxx-Orenstein, A.E.; Grider, J.R. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther., 1999, 288(1), 93-97.
[http://dx.doi.org/10.1124/jpet.103.053256] [PMID: 9862758]
[95]
Nguyen, A.; Camilleri, M.; Kost, L.J.; Metzger, A.; Sarr, M.G.; Hanson, R.B.; Fett, S.L.; Zinsmeister, A.R. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J. Pharmacol. Exp. Ther., 1997, 280(3), 1270-1276.
[PMID: 9067313]
[96]
Schikowski, A.; Thewissen, M.; Mathis, C.; Ross, H.G.; Enck, P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil., 2002, 14(3), 221-227.
[http://dx.doi.org/10.1046/j.1365-2982.2002.00328.x] [PMID: 12061906]
[97]
Coelho, A.M.; Rovira, P.; Fioramonti, J.; Bueno, L. Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology, 2000, 118(4), A835.
[http://dx.doi.org/10.1016/S0016-5085(00)85481-5]
[98]
Hoyer, D.; Fehlmann, D.; Langenegger, D.; Kummer, J.; Giger, R.; Mattes, H.; Probst, A.; Pfannkuche, H.J. High affinity of SDZ HTF-919 related molecules for calf and human caudate 5-HT4 receptors. Ann. N. Y. Acad. Sci., 1998, 861, 267-268.
[http://dx.doi.org/10.1111/j.1749-6632.1998.tb10217.x] [PMID: 9928283]
[99]
Kaumann, A.J. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol. Sci., 1994, 15(12), 451-455.
[http://dx.doi.org/10.1016/0165-6147(94)90058-2] [PMID: 7886817]
[100]
Gershon, M.D. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans. Am. Clin. Climatol. Assoc., 2012, 123, 268-280.
[PMID: 23303993]
[101]
Ghia, J.E.; Li, N.; Wang, H.; Collins, M.; Deng, Y.; El-Sharkawy, R.T.; Côté, F.; Mallet, J.; Khan, W.I. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology, 2009, 137(5), 1649-1660.
[http://dx.doi.org/10.1053/j.gastro.2009.08.041] [PMID: 19706294]
[102]
Bischoff, S.C.; Mailer, R.; Pabst, O.; Weier, G.; Sedlik, W.; Li, Z.; Chen, J.J.; Murphy, D.L.; Gershon, M.D. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(3), G685-G695.
[http://dx.doi.org/10.1152/ajpgi.90685.2008] [PMID: 19095763]
[103]
Traub, R.J.; Pechman, P.; Iadarola, M.J.; Gebhart, G.F. Fos-like proteins in the lumbosacral spinal cord following noxious and non-noxious colorectal distention in the rat. Pain, 1992, 49(3), 393-403.
[http://dx.doi.org/10.1016/0304-3959(92)90247-9] [PMID: 1408305]
[104]
Bueno, L.; Fioramonti, J. Effects of inflammatory mediators on gut sensitivity. Can. J. Gastroenterol., 1999, 13(Suppl. A), 42A-46A.
[http://dx.doi.org/10.1155/1999/846809] [PMID: 10202208]
[105]
Friese, N.; Diop, L.; Chevalier, E.; Angel, F.; Rivière, P.J.; Dahl, S.G. Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul. Pept., 1997, 70(1), 1-7.
[http://dx.doi.org/10.1016/S0167-0115(97)02141-1] [PMID: 9250575]
[106]
Tack, J.; Talley, N.J.; Camilleri, M.; Holtmann, G.; Hu, P.; Malagelada, J.R.; Stanghellini, V. Functional gastroduodenal disorders. Gastroenterology, 2006, 130(5), 1466-1479.
[http://dx.doi.org/10.1053/j.gastro.2005.11.059] [PMID: 16678560]
[107]
Talley, N.J. Drug treatment of functional dyspepsia. Scand. J. Gastroenterol. Suppl., 1991, 182, 47-60.
[PMID: 1896830]
[108]
Ford, A.C.; Marwaha, A.; Sood, R.; Moayyedi, P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut, 2015, 64(7), 1049-1057.
[http://dx.doi.org/10.1136/gutjnl-2014-307843] [PMID: 25147201]
[109]
Degen, L.; Petrig, C.; Studer, D.; Schroller, S.; Beglinger, C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol. Motil., 2005, 17(6), 821-826.
[http://dx.doi.org/10.1111/j.1365-2982.2005.00715.x] [PMID: 16336497]
[110]
Mawe, G.M.; Hoffman, J.M. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol., 2013, 10(8), 473-486.
[http://dx.doi.org/10.1038/nrgastro.2013.105] [PMID: 23797870]
[111]
Vakil, N.; Kianifard, F.; Bottoli, I. Exploratory study of tegaserod for dyspepsia in women receiving PPIs for heartburn. Arch. Drug Inf., 2008, 1(3), 79-88.
[http://dx.doi.org/10.1111/j.1753-5174.2008.00012.x] [PMID: 19639028]
[112]
Appel, S.; Kumle, A.; Hubert, M.; Duvauchelle, T. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J. Clin. Pharmacol., 1997, 37(3), 229-237.
[http://dx.doi.org/10.1002/j.1552-4604.1997.tb04785.x] [PMID: 9089425]
[113]
Merck; Guanidine hydrochloride tablets prescribing information, 2017.Available from: https://www. merck.com/product/usa/pi_circulars/g/guanidine_hydrochloride/guanidine_pi.pdf (Accessed May 17, 2019).
[114]
Novartis. ; Zelnorm (Tegaserod Maleate). Prescribing information, 2007.Available from: https://www. accessdata.fda.gov/drugsatfda_docs/label/2007/02120 0s014lbl.pdf (Accessed May 17, 2019).
[115]
Yan, L.J. Reexploring 5-methoxyindole-2-carboxylic acid (MICA) as a potential antidiabetic agent. Diabetes Metab. Syndr. Obes., 2018, 11, 183-186.
[http://dx.doi.org/10.2147/DMSO.S166485] [PMID: 29765243]
[116]
Appeal-Dingemanse, S.; Lemarechal, M.O.; Kumle, A.; Hubert, M.; Legangneux, E. Integrated modeling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral intravenous administration. J. Clin. Pharmacol., 1999, 47, 483-491.
[http://dx.doi.org/10.1046/j.1365-2125.1999.00936.x]
[117]
Appel-Dingemanse, S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin. Pharmacokinet., 2002, 41(13), 1021-1042.
[http://dx.doi.org/10.2165/00003088-200241130-00002] [PMID: 12403641]
[119]
Zhou, H.; Khalilieh, S.; Lau, H.; Guerret, M.; Osborne, S.; Alladina, L.; Laurent, A.L.; McLeod, J.F. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J. Clin. Pharmacol., 1999, 39(9), 911-919.
[http://dx.doi.org/10.1177/00912709922008524] [PMID: 10471981]
[120]
ZelnormTM (tegaserod maleate) tablets; prescribing information. East Hanover (NJ) Novartis Pharmaceuticas Corporation , 2002.Jul 22; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21200lbl.pdf(Accessed May 17, 2019) .
[121]
Appel-Dingemanse, S.; Hirschberg, Y.; Osborne, S.; Pommier, F.; McLeod, J. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur. J. Clin. Pharmacol., 2001, 56(12), 889-891.
[http://dx.doi.org/10.1007/s002280000239] [PMID: 11317476]
[122]
Appeal-Dingemanse, S.; Rawls, J.; Heggland, J.; Campestrini, J.; Séchaud, R. Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology, 2000, 118(4), A1160.
[http://dx.doi.org/10.1016/S0016-5085(00)80460-6]
[123]
Vickers, A.E.M.; Zollinger, M.; Dannecker, R.; Tynes, R.; Heitz, F.; Fischer, V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab. Dispos., 2001, 29(10), 1269-1276.
[PMID: 11560869]
[124]
Wagstaff, A.J.; Frampton, J.E.; Croom, K.F. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs, 2003, 63(11), 1101-1120.
[http://dx.doi.org/10.2165/00003495-200363110-00013] [PMID: 12749744]
[125]
Prather, C.M.; Camilleri, M.; Zinsmeister, A.R.; McKinzie, S.; Thomforde, G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology, 2000, 118(3), 463-468.
[http://dx.doi.org/10.1016/S0016-5085(00)70251-4] [PMID: 10702196]
[126]
Degen, L.; Matzinger, D.; Merz, M.; Appel-Dingemanse, S.; Osborne, S.; Lüchinger, S.; Bertold, R.; Maecke, H.; Beglinger, C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther., 2001, 15(11), 1745-1751.
[http://dx.doi.org/10.1046/j.1365-2036.2001.01103.x] [PMID: 11683688]
[127]
Degen, L.; Petrig, C.; Studer, D.; Schroller, S.; Beglinger, C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol. Motil., 2005, 17(6), 821-826.
[http://dx.doi.org/10.1111/j.1365-2982.2005.00715.x] [PMID: 16336497]
[128]
Patel, S.; Berrada, D.; Lembo, A. Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin. Pharmacother., 2004, 5(11), 2369-2379.
[http://dx.doi.org/10.1517/14656566.5.11.2369] [PMID: 15500384]
[129]
Müller-Lissner, S.; Koch, G.; Talley, N.J.; Drossman, D.; Rueegg, P.; Dunger-Baldauf, C.; Lefkowitz, M. Subject’s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J. Clin. Epidemiol., 2003, 56(4), 310-316.
[http://dx.doi.org/10.1016/S0895-4356(03)00027-1] [PMID: 12767407]
[130]
Layer, P.; Keller, J.; Loeffler, H.; Kreiss, A. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther. Clin. Risk Manag., 2007, 3(1), 107-118.
[http://dx.doi.org/10.2147/tcrm.2007.3.1.107] [PMID: 18360619]
[131]
Kellow, J.; Chang, O.Y.; Thongsawat, S. Mazlam, M. Z.; Yuen, H.; Gwee, K. A.; Bak, Y. T.; Jones, J.; Wagner, A. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut, 2003, 52, 671-676.
[http://dx.doi.org/10.1136/gut.52.5.671] [PMID: 12692051]
[132]
Chey, W.D. Review article: tegaserod - the global experience. Aliment. Pharmacol. Ther., 2004, 20(Suppl. 7), 15-19.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02181.x] [PMID: 15521850]
[133]
Bardhan, K.D.; Forbes, A.; Marsden, C.L.; Mason, T.; Short, G. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Aliment. Pharmacol. Ther., 2004, 20(2), 213-222.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02032.x] [PMID: 15233702]
[134]
Nyhlin, H.; Bang, C.; Elsborg, L.; Silvennoinen, J.; Holme, I.; Rüegg, P.; Jones, J.; Wagner, A. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand. J. Gastroenterol., 2004, 39(2), 119-126.
[http://dx.doi.org/10.1080/00365520310006748] [PMID: 15000272]
[135]
Layer, P.; Keller, J.; Mueller-Lissner, S.; Rüegg, P.; Loeffler, H. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care. Digestion, 2005, 71(4), 238-244.
[http://dx.doi.org/10.1159/000087049] [PMID: 16024929]
[136]
Thompson, W.G.; Longstreth, G.F.; Drossman, D.A.; Heaton, K.W.; Irvine, E.J.; Müller-Lissner, S.A. Functional bowel disorders and functional abdominal pain. Gut, 1999, 45(Suppl. 2), II43-II47.
[http://dx.doi.org/10.1136/gut.45.2008.ii43] [PMID: 10457044]
[137]
Grant Thompson, W. Tegaserod and IBS: a perfect match? Gut, 2003, 52(5), 621-622.
[http://dx.doi.org/10.1136/gut.52.5.621] [PMID: 12692042]
[138]
Beattie, D.T.; Armstrong, S.R.; Shaw, J.P.; Marquess, D.; Sandlund, C.; Smith, J.A.; Taylor, J.A.; Humphrey, P.P. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 378(1), 139-147.
[http://dx.doi.org/10.1007/s00210-008-0281-z] [PMID: 18408918]
[139]
Seeger, J.D.; Quinn, S.; Earnest, D.L.; Lembo, A.; Kuo, B.; Rivero, E.; Walker, A.M. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol., 2012, 12, 171.
[http://dx.doi.org/10.1186/1471-230X-12-171] [PMID: 23198861]
[140]
Drici, M.D.; Ebert, S.N.; Wang, W.X.; Rodriguez, I.; Liu, X.K.; Whitfield, B.H.; Woosley, R.L. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J. Cardiovasc. Pharmacol., 1999, 34(1), 82-88.
[http://dx.doi.org/10.1097/00005344-199907000-00014] [PMID: 10413072]
[141]
Tack, J.; Camilleri, M.; Chang, L.; Chey, W.D.; Galligan, J.J.; Lacy, B.E.; Müller-Lissner, S.; Quigley, E.M.; Schuurkes, J.; De Maeyer, J.H.; Stanghellini, V. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther., 2012, 35(7), 745-767.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05011.x] [PMID: 22356640]
[142]
Thompson, C.A. Novartis suspends tegaserod sales at FDA’s request. Am. J. Health Syst. Pharm., 2007, 64(10), 1020.
[http://dx.doi.org/10.2146/news070044] [PMID: 17494895]
[143]
Anderson, J.L.; May, H.T.; Bair, T.L.; Muhlestein, J.B.; Horne, B.D.; Carlquist, J.F. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. J. Cardiovasc. Pharmacol. Ther., 2009, 14(3), 170-175.
[http://dx.doi.org/10.1177/1074248409340158] [PMID: 19602672]
[144]
Pasricha, P.J. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology, 2007, 132(7), 2287-2290.
[http://dx.doi.org/10.1053/j.gastro.2007.04.057] [PMID: 17570201]
[145]
Novartis.Press release: Novartis suspends US marketing and sales of Zelnorm in response to request from FDA; Available from: http://hugin.info/134323/R/1116336/204121.pdf (Accessed May 17, 2019).
[146]
Sloan Pharma. Briefing Materials, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees, 2018.Available from: https://www.fda.gov/media/119013/download(Accessed May 17, 2019).
[147]
FDA Briefing Document, Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committees , 2018.Available from: https://www.fda.gov/media/119011/download(Accessed May 17, 2019).
[148]
Busti, A.J.; Murillo, J.R.J., Jr; Cryer, B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy, 2004, 24(4), 526-531.
[http://dx.doi.org/10.1592/phco.24.5.526.33351] [PMID: 15098809]
[149]
Gomez-Mancilla, B.; Cutler, N.R.; Leibowitz, M.T.; Spierings, E.L.; Klapper, J.A.; Diamond, S.; Goldstein, J.; Smith, T.; Couch, J.R.; Fleishaker, J.; Azie, N.; Blunt, D.E. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia, 2001, 21(7), 727-732.
[http://dx.doi.org/10.1046/j.1468-2982.2001.00208.x] [PMID: 11595000]
[150]
Haenisch, B.; Bönisch, H. Pharmacological characterization of tegaserod at the wild type and 124Cys variant of the human 5-HT1B receptor. Pharmacogenet. Genomics, 2011, 21(7), 432-435.
[http://dx.doi.org/10.1097/FPC.0b013e3283469f1d] [PMID: 21478802]
[151]
Chan, K.Y.; de Vries, R.; Leijten, F.P.; Pfannkuche, H.J.; van den Bogaerdt, A.J.; Danser, A.H. MaassenVanDenBrink, A. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur. J. Pharmacol., 2009, 619(1-3), 61-67.
[http://dx.doi.org/10.1016/j.ejphar.2009.07.010] [PMID: 19619527]
[152]
Serebruany, V.L.; El Mouelhi, M.; Pfannkuche, H.J.; Rose, K.; Marro, M.; Angiolillo, D.J. Investigations on 5-HT4 receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am. J. Ther., 2010, 17(6), 543-552.
[http://dx.doi.org/10.1097/MJT.0b013e3181b63f21] [PMID: 19797939]
[153]
US Food & Drug Administration. Zelnorm (tegaserod maleate). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPati entsandProviders/ucm103223.htm(Accessed May 17, 2019).
[154]
US Food & Drug Administration. Zelnorm (tegaserod maleate) Information. Available from: http://www. fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm(Accessed May 17, 2019).
[155]
EMA - Refusal Assessment Report for Zelnorm Procedure No. EMEA/H/C/621. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000621/WC500058849.pdf(Accessed May 17, 2019).


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 4
Year: 2020
Published on: 15 October, 2020
Page: [342 - 369]
Pages: 28
DOI: 10.2174/1871523018666190911121306

Article Metrics

PDF: 34
HTML: 1